Want to see TSE:DOSE full AI Analyst Report?
DOSE Stock Chart & Stats
C$0.14
C$0.02(6.67%)
At close: 4:00 PM EST
C$0.14
C$0.02(6.67%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.20
Previous CloseN/A
Volume31.00K
Average Volume (3M)36.09K
Market Cap
C$14.19M
Enterprise ValueC$18.72M
Total Cash (Recent Filing)C$11.55K
Total Debt (Recent Filing)C$5.32M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding135,181,840
10 Day Avg. Volume35,351
30 Day Avg. Volume36,089
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-2.78
Price to Sales (P/S)7.19
P/FCF Ratio-73.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Oral Thin-film Drug‑delivery PlatformRapid Dose's oral thin‑film delivery platform represents a durable product differentiation versus traditional pills. This technology can address multiple therapeutic and consumer‑health use cases, enabling licensing, formulation partnerships, or niche commercial products that support longer‑term revenue diversification beyond any single drug.
Reduced Cash Burn In The Latest YearA materially smaller cash burn in the most recent year signals improved cost discipline and operational efficiency. If sustained, lower burn extends runway and reduces near‑term financing pressure, enabling the company to advance commercialization or partner negotiations with less frequent capital raises.
Lean Operating Structure (small Headcount)A very small employee base implies low fixed overhead and a capital‑light operating model. For a development/commercialization stage biotech, this increases capital efficiency, allows focused R&D and go‑to‑market activities, and can help preserve cash while pursuing strategic partnerships.
Bears Say
Stressed Balance Sheet With Negative EquityPersistently negative shareholders' equity and rising debt materially weaken financial flexibility. For a small biotech, this elevates refinancing and dilution risk, makes securing favorable financing harder, and reduces the company's ability to withstand adverse development setbacks without significant external capital.
Persistent Negative Cash GenerationOngoing negative operating and free cash flow indicate the business does not self‑fund growth and remains reliant on external capital. This dependence increases dilution risk for shareholders and can constrain strategic choices if capital markets tighten or financing terms worsen over the medium term.
Volatile, Declining Revenue And Negative MarginsRevenue volatility and a recent ~29% decline, coupled with negative gross and operating margins, reflect weak unit economics and limited commercial scale. Without consistent revenue recovery and margin improvement, achieving sustainable profitability will be challenging and may necessitate structural changes or additional capital.
Rapid Dose Therapeutics Corp News
DOSE FAQ
What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?
Rapid Dose Therapeutics Corp lowest stock price was C$0.08 and its highest was C$0.20 in the past 12 months.
What is Rapid Dose Therapeutics Corp’s market cap?
Rapid Dose Therapeutics Corp’s market cap is C$14.19M.
When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?
Rapid Dose Therapeutics Corp’s upcoming earnings report date is Jul 24, 2026 which is today.
How were Rapid Dose Therapeutics Corp’s earnings last quarter?
Currently, no data Available
Is Rapid Dose Therapeutics Corp overvalued?
According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued.
Does Rapid Dose Therapeutics Corp pay dividends?
Rapid Dose Therapeutics Corp does not currently pay dividends.
What is Rapid Dose Therapeutics Corp’s EPS estimate?
Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapid Dose Therapeutics Corp have?
Rapid Dose Therapeutics Corp has 135,181,840 shares outstanding.
What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:DOSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.
Technical Analysis
BriaCell Therapeutics
―
Hemostemix
―
Britannia Life Sciences Inc
―
―
Telescope Innovations Corp
―